Literature DB >> 25316268

Glasgow Prognostic Score predicts poor prognosis among advanced biliary tract cancer patients with good performance status.

Toshikazu Moriwaki1, Kazunori Ishige, Masahiro Araki, Shigemasa Yoshida, Masaaki Nishi, Mikio Sato, Takeshi Yamada, Yoshiyuki Yamamoto, Mitsuharu Ozeki, Hiroyasu Ishida, Takashi Yamaguchi, Kenji Matsuda, Tetsuya Murashita, Masato Abei, Ichinosuke Hyodo.   

Abstract

Advanced cancer patients with good performance status (PS) sometimes show poor prognosis despite receiving some chemotherapies. We evaluated prognosis of chemo-naïve advanced biliary tract cancer (ABTC) patients with good PS by Glasgow Prognostic Score (GPS). Sixty-two patients with Eastern Cooperative Oncology Group PS 0 or 1 were retrospectively analyzed, using multivariate Cox regression. GPS was defined with serum levels of two parameters, albumin >3.5 g/dl and C-reactive protein <1.0 mg/dl (both as 0, either as 1, and neither as 2). PS 0 (n = 32) and 1 (n = 30) patients had similar survival (P = 0.98). The median overall survival (OS) was 17.0 months for GPS 0 (n = 19), 14.2 months for GPS 1 (n = 17), and 6.4 months for GPS 2 (n = 26). GPS 2 had significantly shorter OS than GPS 0 (P = 0.002) or 1 (P = 0.033). Multivariate analysis identified two independent prognostic factors: GPS (hazard ratio 0.60, 95 % confidence interval 0.40-0.90, P = 0.012) and liver metastasis (hazard ratio 0.43, 95 % CI 0.20-0.90, P = 0.026). GPS was useful for chemo-naïve ABTC patients with good PS.

Entities:  

Mesh:

Year:  2014        PMID: 25316268     DOI: 10.1007/s12032-014-0287-y

Source DB:  PubMed          Journal:  Med Oncol        ISSN: 1357-0560            Impact factor:   3.064


  18 in total

1.  The Glasgow Prognostic Score accurately predicts survival in patients with biliary tract cancer not indicated for surgical resection.

Authors:  Akira Iwaku; Akiyoshi Kinoshita; Hiroshi Onoda; Nao Fushiya; Hirokazu Nishino; Masato Matsushima; Hisao Tajiri
Journal:  Med Oncol       Date:  2013-12-06       Impact factor: 3.064

2.  FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.

Authors:  Thierry Conroy; Françoise Desseigne; Marc Ychou; Olivier Bouché; Rosine Guimbaud; Yves Bécouarn; Antoine Adenis; Jean-Luc Raoul; Sophie Gourgou-Bourgade; Christelle de la Fouchardière; Jaafar Bennouna; Jean-Baptiste Bachet; Faiza Khemissa-Akouz; Denis Péré-Vergé; Catherine Delbaldo; Eric Assenat; Bruno Chauffert; Pierre Michel; Christine Montoto-Grillot; Michel Ducreux
Journal:  N Engl J Med       Date:  2011-05-12       Impact factor: 91.245

Review 3.  The systemic inflammation-based Glasgow Prognostic Score: a decade of experience in patients with cancer.

Authors:  Donald C McMillan
Journal:  Cancer Treat Rev       Date:  2012-09-17       Impact factor: 12.111

4.  Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer.

Authors:  Juan Valle; Harpreet Wasan; Daniel H Palmer; David Cunningham; Alan Anthoney; Anthony Maraveyas; Srinivasan Madhusudan; Tim Iveson; Sharon Hughes; Stephen P Pereira; Michael Roughton; John Bridgewater
Journal:  N Engl J Med       Date:  2010-04-08       Impact factor: 91.245

5.  Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologico Nord Ovest.

Authors:  Alfredo Falcone; Sergio Ricci; Isa Brunetti; Elisabetta Pfanner; Giacomo Allegrini; Cecilia Barbara; Lucio Crinò; Giovanni Benedetti; Walter Evangelista; Laura Fanchini; Enrico Cortesi; Vincenzo Picone; Stefano Vitello; Silvana Chiara; Cristina Granetto; Gianfranco Porcile; Luisa Fioretto; Cinzia Orlandini; Michele Andreuccetti; Gianluca Masi
Journal:  J Clin Oncol       Date:  2007-05-01       Impact factor: 44.544

6.  FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial.

Authors:  Volker Heinemann; Ludwig Fischer von Weikersthal; Thomas Decker; Alexander Kiani; Ursula Vehling-Kaiser; Salah-Eddin Al-Batran; Tobias Heintges; Christian Lerchenmüller; Christoph Kahl; Gernot Seipelt; Frank Kullmann; Martina Stauch; Werner Scheithauer; Jörg Hielscher; Michael Scholz; Sebastian Müller; Hartmut Link; Norbert Niederle; Andreas Rost; Heinz-Gert Höffkes; Markus Moehler; Reinhard U Lindig; Dominik P Modest; Lisa Rossius; Thomas Kirchner; Andreas Jung; Sebastian Stintzing
Journal:  Lancet Oncol       Date:  2014-07-31       Impact factor: 41.316

7.  Comparison of an inflammation-based prognostic score (GPS) with performance status (ECOG-ps) in patients receiving palliative chemotherapy for gastroesophageal cancer.

Authors:  Andrew B C Crumley; Robert C Stuart; Margaret McKernan; Alexander C McDonald; Donald C McMillan
Journal:  J Gastroenterol Hepatol       Date:  2007-07-20       Impact factor: 4.029

8.  Inflammation-based prognostic score is a useful predictor of postoperative outcome in patients with extrahepatic cholangiocarcinoma.

Authors:  Yukio Oshiro; Ryoko Sasaki; Kiyoshi Fukunaga; Tadashi Kondo; Tatsuya Oda; Hideto Takahashi; Nobuhiro Ohkohchi
Journal:  J Hepatobiliary Pancreat Sci       Date:  2013-03       Impact factor: 7.027

9.  Gemcitabine alone or in combination with cisplatin in patients with biliary tract cancer: a comparative multicentre study in Japan.

Authors:  T Okusaka; K Nakachi; A Fukutomi; N Mizuno; S Ohkawa; A Funakoshi; M Nagino; S Kondo; S Nagaoka; J Funai; M Koshiji; Y Nambu; J Furuse; M Miyazaki; Y Nimura
Journal:  Br J Cancer       Date:  2010-07-13       Impact factor: 7.640

10.  Prognostic significance of a systemic inflammatory response in patients receiving first-line palliative chemotherapy for recurred or metastatic gastric cancer.

Authors:  Jun-Eul Hwang; Ha-Na Kim; Dae-Eun Kim; Hyun-Jung Choi; Sung-Hoon Jung; Hyun-Jeong Shim; Woo-Kyun Bae; Eu-Chang Hwang; Sang-Hee Cho; Ik-Joo Chung
Journal:  BMC Cancer       Date:  2011-11-21       Impact factor: 4.430

View more
  12 in total

1.  Hyperfibrinogenemia predicts poor prognosis in patients with advanced biliary tract cancer.

Authors:  Heming Li; Tong Zhao; Xuening Ji; Shanshan Liang; Zhe Wang; Yulong Yang; Jiajun Yin; Ruoyu Wang
Journal:  Tumour Biol       Date:  2015-10-09

2.  Preoperative lymphocyte-monocyte and platelet-lymphocyte ratios as predictors of overall survival in patients with bladder cancer undergoing radical cystectomy.

Authors:  Gui-Ming Zhang; Yao Zhu; Lei Luo; Fang-Ning Wan; Yi-Ping Zhu; Li-Jiang Sun; Ding-Wei Ye
Journal:  Tumour Biol       Date:  2015-06-02

3.  A systematic review of the overlap of fluid biomarkers in delirium and advanced cancer-related syndromes.

Authors:  Ingrid Amgarth-Duff; Annmarie Hosie; Gideon Caplan; Meera Agar
Journal:  BMC Psychiatry       Date:  2020-04-22       Impact factor: 3.630

4.  The prognostic impact of neutrophil-to-lymphocyte ratio (NLR) and lymphocyte-to-monocyte ratio (LMR) in patients with distal bile duct cancer.

Authors:  Yoji Miyahara; Shida Takashi; Yoshiaki Shimizu; Masayuki Ohtsuka
Journal:  World J Surg Oncol       Date:  2020-04-22       Impact factor: 2.754

5.  Nomogram-based prediction of survival in unresectable or metastatic gastric cancer patients with good performance status who received first-line chemotherapy.

Authors:  Jin Wang; Bowen Yang; Zhi Li; Jinglei Qu; Jing Liu; Na Song; Ying Chen; Yu Cheng; Simeng Zhang; Zhongqing Wang; Xiujuan Qu; Yunpeng Liu
Journal:  Ann Transl Med       Date:  2020-03

6.  Clinical prognostic scores for patients with thymic epithelial tumors.

Authors:  Cecilia Veraar; Stefan Janik; Jürgen Thanner; Clarence Veraar; Mohamed Mouhieddine; Ana-Iris Schiefer; Leonhard Müllauer; Martin Dworschak; Walter Klepetko; Hendrik Jan Ankersmit; Bernhard Moser
Journal:  Sci Rep       Date:  2019-12-09       Impact factor: 4.379

7.  Pretreatment Neutrophil-to-Lymphocyte Ratio: A Predictor of Advanced Prostate Cancer and Biochemical Recurrence in Patients Receiving Radical Prostatectomy.

Authors:  Gui-Ming Zhang; Yao Zhu; Xiao-Cheng Ma; Xiao-Jian Qin; Fang-Ning Wan; Bo Dai; Li-Jiang Sun; Ding-Wei Ye
Journal:  Medicine (Baltimore)       Date:  2015-10       Impact factor: 1.817

8.  A Prognostic Model in Metastatic or Recurrent Gastric Cancer Patients with Good Performance Status Who Received First-Line Chemotherapy.

Authors:  Jin Wang; Jinglei Qu; Zhi Li; Xiaofang Che; Jingdong Zhang; Jing Liu; Yuee Teng; Bo Jin; Mingfang Zhao; Yunpeng Liu; Xiujuan Qu
Journal:  Transl Oncol       Date:  2016-06       Impact factor: 4.243

9.  Glasgow prognostic score is superior to other inflammation-based scores in predicting survival of diffuse large B-cell lymphoma.

Authors:  Xiaoxiao Hao; Yongqiang Wei; Xiaolei Wei; Lizhi Zhou; Qi Wei; Yuankun Zhang; Weimin Huang; Ru Feng
Journal:  Oncotarget       Date:  2017-09-11

10.  The Glasgow Prognostic Score at Diagnosis Is a Predictor of Clinical Outcome in Patients with Multiple Myeloma Undergoing Autologous Haematopoietic Stem Cell Transplantation.

Authors:  Hanno M Witte; Bastian Bonorden; Armin Riecke; Harald Biersack; Konrad Steinestel; Hartmut Merz; Alfred C Feller; Veronica Bernard; Sebastian Fetscher; Nikolas von Bubnoff; Niklas Gebauer
Journal:  Cancers (Basel)       Date:  2020-04-09       Impact factor: 6.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.